ECOG-ACRIN logoECOG-ACRIN logoECOG-ACRIN logoECOG-ACRIN logo
  • Home
  • Contact
✕

Blog

  • Home
  • Blog

News, editorials, and perspectives for the cancer research advocacy community

✕

Categories

  • Editorials
  • New Trials
  • Ongoing Trials
  • Trial Results

Archives

  • June 2022
  • March 2022
  • December 2021
  • September 2021
  • June 2021
  • March 2021
  • October 2020
  • June 2020
  • February 2020
  • October 2019

Resources

  • Active ECOG-ACRIN Trials
  • Advocacy Organizations
  • Myths and Facts

Tags

Acute lymphoblastic leukemia Adolescents and young adults Antioxidants Blood cancers Breast cancer Cancer care delivery Caregiving Chronic lymphocytic leukemia Communication De-escalation Green tea Head and neck cancer Health equity HER2+ breast cancer Immune system therapy Immunotherapy Kidney cancer Language Late Effects Leukemia Lung cancer Lymphoma Mammography Mantle cell lymphoma Melanoma Mesothelioma Minimal residual disease Multiple myeloma Myeloma NCI-MATCH Neuropathy Older adults Pancreatic cancer Patient-reported outcomes Personalized medicine Personalized screening Personalized treatment Precision medicine Prevention Prostate cancer Screening Surveillance Survivorship Targeted therapy Throat cancer
STAY UP TO DATE

Subscribe to receive updates from the ECOG-ACRIN advocacy committee.

Select list(s) to subscribe to

By submitting this form, you are consenting to receive marketing emails from: ECOG-ACRIN Cancer Research Group, 1818 Market Street, Philadelphia, PA, 19103, http://ecog-acrin.org. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact


Office of Communications
1818 Market Street, Suite 3000
Philadelphia, PA 19103
Phone: 215.789.3631
www.ecog-acrin.org

Contact us with any questions

© 2012-2022 ECOG-ACRIN Cancer Research Group. All Rights Reserved. Designed by Create & Associates, Inc